Literature DB >> 17915575

Molecular genetics of late onset glycogen storage disease II in Italy.

M G Pittis1, M Filocamo.   

Abstract

Glycogen Storage Disease Type II (GSDII) is a recessively inherited disorder due to the deficiency of acid alpha-glucosidase (GAA) that results in glycogen accumulation in the lysosomes. The molecular analysis of the GAA gene was performed on 45 Italian patients with late onset GSDII. DHPLC analysis revealed 28 polymorphisms spread all over the GAA gene. Direct sequencing identified the 96% of the mutant alleles, 12 of which are novel. Missense mutations were functionally characterized by enzyme activity and protein processing in a human GAA deficient cell line while splicing mutations were studied by RT-PCR and in silico analysis. A complex allele was also identified carrying three different alterations in cis. All the patients studied carried a severe mutation in combination with a milder one, which explains the late onset of the disease. The c.-32-13T > G was the most frequent mutation, present as compound heterozygote in 85% of the patients as described in other late onset GSDII Caucasian populations. Interestingly, 10 of the 45 patients carried the c.-32-13T > G associated to the severe c.2237G > A (p.W746X) mutation. However, despite the common genotype, patients presented with a wide variability in residual enzyme activity, age of appearance of clinical signs and rate of disease progression, suggesting that other genetic/environment factors may modulate clinical presentation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915575      PMCID: PMC2949324     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  20 in total

1.  Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

2.  Standardizing mutation nomenclature: why bother?

Authors:  Johan T den Dunnen; Mark H Paalman
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

3.  Characterization of the human lysosomal alpha-glucosidase gene.

Authors:  L H Hoefsloot; M Hoogeveen-Westerveld; A J Reuser; B A Oostra
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

4.  Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells.

Authors:  L H Hoefsloot; R Willemsen; M A Kroos; M Hoogeveen-Westerveld; M M Hermans; A T Van der Ploeg; B A Oostra; A J Reuser
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

5.  Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation.

Authors:  P Laforêt; M Nicolino; P B Eymard; J P Puech; C Caillaud; L Poenaru; M Fardeau
Journal:  Neurology       Date:  2000-10-24       Impact factor: 9.910

Review 6.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

Authors:  Nina Raben; Paul Plotz; Barry J Byrne
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

7.  Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease.

Authors:  Anna Lisa E Montalvo; Roberta Cariati; Marta Deganuto; Veronica Guerci; Rodolfo Garcia; Giovanni Ciana; Bruno Bembi; Maria Gabriela Pittis
Journal:  Mol Genet Metab       Date:  2004-03       Impact factor: 4.797

Review 8.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.

Authors:  Hannerieke M P van den Hout; Wim Hop; Otto P van Diggelen; Jan A M Smeitink; G Peter A Smit; Bwee-Tien T Poll-The; Henk D Bakker; M Christa B Loonen; Johannis B C de Klerk; Arnold J J Reuser; Ans T van der Ploeg
Journal:  Pediatrics       Date:  2003-08       Impact factor: 7.124

Review 9.  Pompe disease in infants and children.

Authors:  Priya Sunil Kishnani; R Rodney Howell
Journal:  J Pediatr       Date:  2004-05       Impact factor: 4.406

10.  Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II.

Authors:  A L E Montalvo; B Bembi; M Donnarumma; M Filocamo; G Parenti; M Rossi; L Merlini; E Buratti; P De Filippi; A Dardis; M Stroppiano; G Ciana; M G Pittis
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

View more
  5 in total

Review 1.  Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.

Authors:  Gauthier Remiche; Dario Ronchi; Francesca Magri; Costanza Lamperti; Andreina Bordoni; Maurizio Moggio; Nereo Bresolin; Giacomo P Comi
Journal:  J Neurol       Date:  2013-10-25       Impact factor: 4.849

2.  Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.

Authors:  Federica Montagnese; E Barca; O Musumeci; S Mondello; A Migliorato; A Ciranni; C Rodolico; P De Filippi; C Danesino; A Toscano
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

3.  Genetic counseling in Pompe disease.

Authors:  Antonella Taglia; Esther Picillo; Paola D'Ambrosio; Maria Rosaria Cecio; Emanuela Viggiano; Luisa Politano
Journal:  Acta Myol       Date:  2011-12

4.  Broad variation in phenotypes for common GAA genotypes in Pompe disease.

Authors:  Monica Y Niño; Stijn L M In't Groen; Douglas O S de Faria; Marianne Hoogeveen-Westerveld; Hannerieke J M P van den Hout; Ans T van der Ploeg; Atze J Bergsma; W W M Pim Pijnappel
Journal:  Hum Mutat       Date:  2021-09-08       Impact factor: 4.700

5.  Genotype-phenotype correlation in Pompe disease, a step forward.

Authors:  Paola De Filippi; Kolsoum Saeidi; Sabrina Ravaglia; Andrea Dardis; Corrado Angelini; Tiziana Mongini; Lucia Morandi; Maurizio Moggio; Antonio Di Muzio; Massimiliano Filosto; Bruno Bembi; Fabio Giannini; Giovanni Marrosu; Miriam Rigoldi; Paola Tonin; Serenella Servidei; Gabriele Siciliano; Annalisa Carlucci; Claudia Scotti; Mario Comelli; Antonio Toscano; Cesare Danesino
Journal:  Orphanet J Rare Dis       Date:  2014-08-08       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.